Aspartate beta-hydroxylase domain-containing protein 2 (ASPHD2)

Aspartate beta-hydroxylase domain-containing protein 2 (ASPHD2) is a membrane-associated protein predicted to act as a **2-oxoglutarate-dependent dioxygenase** with metal ion binding capacity[4][1][3][5]. It is most closely related to the beta-hydroxylase enzyme family, which broadly participates in key developmental and oncogenic processes. The precise biochemical function of ASPHD2 remains incompletely defined, but gene expression and proteomic data indicate that it is **upregulated in glioma and tuberculosis**, particularly in response to hypoxic or inflammatory signals[1][2]. In glioblastomas, ASPHD2 is part of a tumor stem cell gene signature; its expression is increased under hypoxic conditions regulated by hypoxia-inducible factor 2α and may contribute to aggressive tumor phenotypes by supporting stem cell maintenance[1]. In tuberculosis, ASPHD2 expression is elevated in both pulmonary and extrapulmonary disease, and its levels decrease with effective therapy, indicating its potential use as a **treatment response biomarker**[2]. While ASPHD2 is inferred to impact immune signaling, cell survival under stress, and possibly Notch pathway modulation (paralleling other beta-hydroxylases), no direct drug interactions or approved therapeutics targeting ASPHD2 are currently documented[2][4][1].

Other names

FLJ39838ASPH2aspartate beta-hydroxylase domain-containing 2